RECURSION PHARMACEUTICALS, INC. Revenue
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Revenue of $7.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $7.67M, a 60.10% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $6.47M, a 56.11% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $35.54M, a 681.74% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $5.17M, a 80.16% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $74.68M, a 26.92% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $58.84M, a 32.00% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $44.58M, a 11.88% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $39.84M, a 291.46% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.67M 10-Q · filed 2026-08-05 | $14.14M 10-Q · filed 2026-08-05 | $49.68M derived: sum of 3 quarters · filed 2026-08-05 | $54.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $6.47M 10-Q · filed 2026-05-06 | $42.01M derived: sum of 2 quarters · filed 2026-05-06 | $47.19M derived: sum of 3 quarters · filed 2026-05-06 | $66.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $35.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $40.71M derived: sum of 2 quarters · filed 2026-02-25 | $59.94M derived: sum of 3 quarters · filed 2026-08-05 | $74.68M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.17M 10-Q · filed 2025-11-05 | $24.40M derived: sum of 2 quarters · filed 2026-08-05 | $39.14M 10-Q · filed 2025-11-05 | $43.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $19.22M 10-Q · filed 2026-08-05 | $33.97M 10-Q · filed 2026-08-05 | $38.51M derived: sum of 3 quarters · filed 2026-08-05 | $64.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $14.74M 10-Q · filed 2026-05-06 | $19.29M derived: sum of 2 quarters · filed 2026-05-06 | $45.37M derived: sum of 3 quarters · filed 2026-05-06 | $59.79M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $30.63M derived: sum of 2 quarters · filed 2026-02-25 | $45.05M derived: sum of 3 quarters · filed 2026-02-25 | $58.84M 10-K · filed 2026-02-25 |
| 2024-09-30 | $26.08M 10-Q · filed 2025-11-05 | $40.50M derived: sum of 2 quarters · filed 2025-11-05 | $54.29M 10-Q · filed 2025-11-05 | $65.18M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $14.42M 10-Q · filed 2025-08-05 | $28.21M 10-Q · filed 2025-08-05 | $39.10M derived: sum of 3 quarters · filed 2026-02-25 | $49.63M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $13.79M 10-Q · filed 2025-05-05 | $24.68M derived: sum of 2 quarters · filed 2026-02-25 | $35.22M derived: sum of 3 quarters · filed 2026-02-25 | $46.23M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $21.42M derived: sum of 2 quarters · filed 2026-02-25 | $32.44M derived: sum of 3 quarters · filed 2026-02-25 | $44.58M 10-K · filed 2026-02-25 |
| 2023-09-30 | $10.53M 10-Q · filed 2024-11-06 | $21.55M derived: sum of 2 quarters · filed 2024-11-06 | $33.68M 10-Q · filed 2024-11-06 | $47.36M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $11.02M 10-Q · filed 2024-08-08 | $23.15M 10-Q · filed 2024-08-08 | $36.83M derived: sum of 3 quarters · filed 2025-02-28 | $49.99M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $12.13M 10-Q · filed 2024-05-09 | $25.81M derived: sum of 2 quarters · filed 2025-02-28 | $38.97M derived: sum of 3 quarters · filed 2025-02-28 | $46.64M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $13.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $26.84M derived: sum of 2 quarters · filed 2025-02-28 | $34.51M derived: sum of 3 quarters · filed 2025-02-28 | $39.84M 10-K · filed 2025-02-28 |
| 2022-09-30 | $13.16M 10-Q · filed 2023-11-09 | $20.83M derived: sum of 2 quarters · filed 2023-11-09 | $26.17M 10-Q · filed 2023-11-09 | $28.70M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $7.67M 10-Q · filed 2023-08-08 | $13.01M 10-Q · filed 2023-08-08 | $15.54M derived: sum of 3 quarters · filed 2024-02-29 | $18.07M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $5.33M 10-Q · filed 2023-05-08 | $7.87M derived: sum of 2 quarters · filed 2024-02-29 | $10.40M derived: sum of 3 quarters · filed 2024-02-29 | $12.95M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.07M derived: sum of 2 quarters · filed 2024-02-29 | $7.62M derived: sum of 3 quarters · filed 2024-02-29 | $10.18M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.53M 10-Q · filed 2022-11-08 | $5.08M derived: sum of 2 quarters · filed 2022-11-08 | $7.64M 10-Q · filed 2022-11-08 | $10.34M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $2.55M 10-Q · filed 2022-08-09 | $5.11M 10-Q · filed 2022-08-09 | $7.80M derived: sum of 3 quarters · filed 2023-02-27 | $8.83M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.56M 10-Q · filed 2022-05-10 | $5.25M derived: sum of 2 quarters · filed 2023-02-27 | $6.28M derived: sum of 3 quarters · filed 2023-02-27 | $6.46M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $3.72M derived: sum of 2 quarters · filed 2023-02-27 | $3.90M derived: sum of 3 quarters · filed 2023-02-27 | $3.96M 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.02M 10-Q · filed 2021-11-10 | $1.21M derived: sum of 2 quarters · filed 2021-11-10 | $1.27M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $186.00K 10-Q · filed 2021-08-13 | $246.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $60.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $2.32M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |